INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA
Record quarterly clinic revenues supported by both organic growth and acquisitions
Seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA
Balance sheet continues to improve following debt repayments
SARASOTA, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility”, “INVO”, or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the third quarter ended September 30, 2026.
Q3 2026 Financial Highlights (all metrics compared to Q3 2025 unless otherwise noted)
- Revenue increased 26% to $2,222,656 from $1,757,094.
- Consolidated clinic revenue increased 28% to $2,207,587 from $1,722,223.
- Net loss narrowed to $2.1 million from $3.4 million. Loss from operations improved to $1.5 million from $1.6 million.
- Clinic-Level Adjusted EBITDA before corporate operating and public company expenses remained positive for the seventh consecutive quarter.
- Consolidated Adjusted EBITDA was $(1.0) million, compared to $(0.9) million in Q3 2025.
- Cash was $3.7 million at September 30, 2026, or approximately $3.10 per share.
- As of November 13, 2026, the Company had 1,192,860 shares of common stock outstanding.
- Further strengthening of the balance sheet compared to December 31, 2025 with assets increasing by $5.3 million, liabilities reduced by $5.5 million, and net equity of $18.0 million, or $15.09 per share.
Recent Highlights
- Organic and acquired growth. Revenue grew at both the Wisconsin and Atlanta clinics as the practices continued their efforts to reach more patients. Management believes that Wisconsin’s entry into the Progyny network in the first quarter contributed to growth by expanding access for patients with Progyny coverage. The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each contributed a full quarter of revenue.
- Clinic efficiency. INVO has implemented, and continues to evaluate, new tools to reduce time spent on documentation and administrative work across its practices, drawing on industry best practice. These initiatives are expected to continue driving improved patient experience and clinic-level efficiencies.
- Positive industry feedback at ASRM. In October 2026, INVO attended the American Society for Reproductive Medicine Scientific Congress & Expo in Baltimore, resulting in further expansion of potential acquisition opportunities.
- Improved balance sheet. INVO ended September with $3.7 million in cash and $4.5 million in current liabilities, down from $10.3 million in current liabilities at year-end 2025.
- Planned investment in Birmingham. In June 2026, INVO acquired the remaining 50% interest in its Birmingham clinic for an agreed purchase price of $175,001 payable to the sellers. The purchase price reflected the investments INVO expected to make under full ownership, including recruiting a new physician and adding key services, and the temporary revenue disruption as the new physician ramps up.
- Continued clinic-level profitability. The clinic network generated approximately $292,000 in Clinic-Level Adjusted EBITDA, its seventh consecutive positive quarter, after accounting for the approximate $193,000 impact in Q3 of the planned Birmingham acquisition transitioning.
Management Commentary
“Revenue grew again this quarter, and our clinics continued to generate positive Adjusted EBITDA before corporate expenses,” said Steve Shum, Chief Executive Officer of INVO Fertility. “We saw growth at our Wisconsin and Atlanta practices alongside the contribution from our acquisitions of the Indiana clinic and Birmingham clinic. That combination is what we set out to achieve by investing in our existing clinics and acquiring established practices.”
“We continue to see increased opportunities for acquisitions, which remain a key component to our growth objectives, as independent fertility practices look for ways to serve more patients while preserving the local relationships that patients and physicians value. As a publicly traded fertility clinic operator, INVO provides public market investors an alternative way to participate directly in that evolution and share in the potential growth of our clinic network. Equally important, we have purposely made key investments in people and additional infrastructure, in advance, in preparation to expand our network. We believe we have assembled an excellent team capable of executing on our growth plans and we look forward to leveraging our infrastructure as we expand and driving further operating performance.”
“Our balance sheet has also further strengthened in the period following the Wisconsin acquisition payment and the reduction in our current liabilities. We’re also focused on helping our clinics reach more patients and giving our clinical teams better tools and resources. Overall, the progress we’ve made and the opportunities we see on both sides of our growth strategy give us good reason to be excited about what comes next,” Shum concluded.
Third Quarter Financial Discussion
Revenue increased to approximately $2.2 million in the third quarter of 2026 from approximately $1.8 million in the prior-year quarter. Clinic revenue accounted for approximately $485,000 of year-over-year growth, reflecting higher revenue in Wisconsin and Atlanta and the addition of the Indiana and Birmingham clinics. Product revenue was approximately $15,000, compared to approximately $35,000 a year earlier. The decrease in product revenue partially reflects the elimination of sales to the Indiana and Birmingham clinics, which are now consolidated subsidiaries and treated as intercompany transactions.
Cost of services was approximately $1.4 million in the third quarter of 2026, primarily reflecting the cost of providing care across the expanded clinic network. Selling, general, and administrative expenses were approximately $2.1 million, compared to approximately $2.1 million a year earlier.
Loss from operations improved to approximately $1.5 million in the third quarter of 2026 from $1.6 million in the prior year. Net loss narrowed to approximately $2.1 million from approximately $3.4 million in the year-ago quarter.
Consolidated Adjusted EBITDA was $(1.0) million in the third quarter of 2026, compared with $(0.9) million in the prior-year quarter. This measure includes the cost of operating the public company and supporting the clinic network, including personnel in operations, human resources, and finance.
Clinic-Level Adjusted EBITDA was $292,114, compared with $243,120 in the prior-year quarter. The clinics generated positive Adjusted EBITDA before corporate expenses for the seventh consecutive quarter. The planned transition in Birmingham reduced the quarter’s clinic-level contribution by approximately $193,000 due to the anticipated revenue disruption and increased costs associated with bringing in a new physician.
At September 30, 2026, cash totaled approximately $3.7 million and current liabilities were approximately $4.5 million, compared to $2.1 million and $10.3 million, respectively, at December 31, 2025.
Clinic-Level Adjusted EBITDA
Clinic-Level Adjusted EBITDA was $292,114 in the third quarter of 2026, compared with $243,120 in the third quarter of 2025. The clinic network generated positive Adjusted EBITDA for the seventh consecutive quarter.
Management is focused on growing this contribution through higher patient volumes, expanded services, and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.
(Unaudited, in dollars, before corporate operating and public company expenses)
| Fertility Clinic Services Segment | Q3 2026 | Q3 2025 |
| Clinic revenue | $2,207,587 | $1,722,223 |
| Operating expenses | 2,144,678 | 1,592,534 |
| Segment profit | 62,909 | 129,689 |
| Depreciation and amortization | 36,273 | 113,431 |
| Birmingham clinic – acquisition transition | 192,932 | - |
| Clinic-Level Adjusted EBITDA | $292,114 | $243,120 |
Clinic-Level Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures and the reconciliation below. Fertility Clinic Services Segment data derived from Note 15 – Segment Reporting in the Company’s third quarter 10-Q
Webcast
INVO Fertility will host a webcast to discuss its third quarter 2026 financial results and provide a business update.
Date and time:Monday, November 16, 2026, at 11:00 a.m. Eastern Time
Webcast registration:https://app.webinar.net/2WBLVyGJEq9
Replay:https://app.webinar.net/2WBLVyGJEq9
Use of Non-GAAP Measure
Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA, which are non-GAAP financial measures. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles. Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.
Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
| INVO FERTILITY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Clinic revenue | $ | 2,207,587 | $ | 1,722,223 | $ | 6,357,605 | $ | 5,175,870 | ||||||||
| Product revenue | 15,069 | 34,871 | 55,761 | 82,063 | ||||||||||||
| Total revenue | 2,222,656 | 1,757,094 | 6,413,366 | 5,257,933 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of services | 1,436,870 | 1,121,174 | 4,071,782 | 3,252,659 | ||||||||||||
| Cost of goods sold | 14,144 | 6,575 | 79,443 | 13,622 | ||||||||||||
| Selling, general, and administrative expenses | 2,071,438 | 2,128,088 | 6,154,287 | 5,878,459 | ||||||||||||
| Impairment loss | - | - | - | 1,397,353 | ||||||||||||
| Depreciation and amortization | 177,564 | 136,741 | 465,835 | 540,940 | ||||||||||||
| Total operating expenses | 3,700,016 | 3,392,578 | 10,771,347 | 11,083,033 | ||||||||||||
| Loss from operations | (1,477,360 | ) | (1,635,484 | ) | (4,357,981 | ) | (5,825,100 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Gain from equity method joint ventures | - | 12,827 | 15,014 | 8,012 | ||||||||||||
| Gain on remeasurement | - | - | 2,452,032 | - | ||||||||||||
| Gain (loss) on change in fair value of derivatives | (562,997 | ) | (33,566 | ) | (4,353,222 | ) | 1,626,594 | |||||||||
| Loss on debt extinguishment | - | (1,416,610 | ) | (172,621 | ) | (2,108,880 | ) | |||||||||
| Gain on settlement | - | - | - | 939,500 | ||||||||||||
| Interest income | 74,735 | - | 214,249 | - | ||||||||||||
| Interest expense | (154,768 | ) | (322,765 | ) | (512,318 | ) | (1,071,200 | ) | ||||||||
| Total other income (expense) | (643,030 | ) | (1,760,114 | ) | (2,356,866 | ) | (605,974 | ) | ||||||||
| Net loss from continuing operations before income taxes | (2,120,390 | ) | (3,395,598 | ) | (6,714,847 | ) | (6,431,074 | ) | ||||||||
| Provision for income taxes | 29,530 | - | 85,684 | - | ||||||||||||
| Net loss from continuing operations | (2,149,920 | ) | (3,395,598 | ) | (6,800,531 | ) | (6,431,074 | ) | ||||||||
| Discontinued operations (Note 5) | ||||||||||||||||
| Loss on disposal of NTI | - | - | - | (1,534,517 | ) | |||||||||||
| Loss on discontinued operations of NTI | - | - | - | (16,452,562 | ) | |||||||||||
| Net loss | $ | (2,149,920 | ) | $ | (3,395,598 | ) | $ | (6,800,531 | ) | $ | (24,418,153 | ) | ||||
| Net Loss from continuing operations per share | ||||||||||||||||
| Basic | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (722.84 | ) | ||||
| Diluted | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (722.84 | ) | ||||
| Loss from discontinued operations per common share | ||||||||||||||||
| Basic | $ | - | $ | - | $ | - | $ | (2,021.70 | ) | |||||||
| Diluted | $ | - | $ | - | $ | - | $ | (2,021.70 | ) | |||||||
| Net Loss per common share: | ||||||||||||||||
| Basic | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (2,744.54 | ) | ||||
| Diluted | $ | (2.44 | ) | $ | (157.43 | ) | $ | (11.20 | ) | $ | (2,744.54 | ) | ||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 880,233 | 21,569 | 607,101 | 8,897 | ||||||||||||
| Diluted | 880,233 | 21,569 | 607,101 | 8,897 | ||||||||||||
| INVO FERTILITY, INC. CONSOLIDATED BALANCE SHEETS | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 3,695,770 | $ | 2,077,842 | ||||
| Accounts receivable, net of allowances of $140,089 and $69,641 as of September 30, 2026 and December 31, 2025, respectively | 170,423 | 217,263 | ||||||
| Inventory, net of allowances of $0 as of September 30, 2026 and December 31, 2025 | 230,806 | 225,253 | ||||||
| Prepaid expenses and other current assets | 347,840 | 241,145 | ||||||
| Total current assets | 4,444,839 | 2,761,503 | ||||||
| Property and equipment, net | 814,175 | 386,165 | ||||||
| Lease right of use | 2,052,056 | 1,286,217 | ||||||
| Intangible assets, net | 1,245,345 | 1,325,145 | ||||||
| Goodwill | 9,236,642 | 5,878,986 | ||||||
| Investment in NAYA Therapeutics | 2,466,810 | 2,466,810 | ||||||
| Note receivable – NAYA Therapeutics | 5,240,333 | 5,029,770 | ||||||
| Note receivable – HRCFG | - | 1,085,528 | ||||||
| Total assets | $ | 25,500,200 | $ | 20,220,124 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 1,297,870 | $ | 2,034,057 | ||||
| Accrued compensation | 377,110 | 285,946 | ||||||
| Notes payable - current portion, net | 577,108 | 394,664 | ||||||
| Convertible note payable - related party, net | 17,882 | 880,000 | ||||||
| Deferred revenue | 728,630 | 721,897 | ||||||
| Lease liability, current portion | 413,117 | 208,987 | ||||||
| Additional payments for acquisitions, current portion | 998,000 | 3,925,000 | ||||||
| Warrant liability | - | 1,881,078 | ||||||
| Other current liabilities | 47,812 | - | ||||||
| Total current liabilities | 4,457,529 | 10,331,629 | ||||||
| Lease liability, net of current portion | 1,769,838 | 1,171,075 | ||||||
| Liability for excess losses of equity method investee | - | 448,474 | ||||||
| Notes payable – net of current portion | 362,445 | 744,725 | ||||||
| Derivative liability | 745,288 | - | ||||||
| Deferred tax liability | 80,159 | - | ||||||
| Other liabilities, net of current portion | 79,688 | - | ||||||
| Additional payments for acquisition, net of current portion | - | 300,000 | ||||||
| Total liabilities | $ | 7,494,947 | $ | 12,995,903 | ||||
| Stockholders’ equity | ||||||||
| Series C-2 Preferred Stock, $1,000.00 par value; 20,000 shares authorized; 0 and 3,004 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | $ | - | $ | 2,406,359 | ||||
| Series D Preferred Stock, $1,000.00 par value, 400 shares authorized; 400 and 0 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 400,000 | - | ||||||
| Common Stock, $.0001 par value; 62,500,000 shares authorized; 1,192,860 and 119,358 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 119 | 11 | ||||||
| Additional paid-in capital | 115,790,672 | 96,187,254 | ||||||
| Accumulated deficit | (98,185,538 | ) | (91,369,403 | ) | ||||
| Total stockholders’ equity | 18,005,253 | 7,224,221 | ||||||
| Total liabilities and stockholders’ equity | $ | 25,500,200 | $ | 20,220,124 | ||||
| Adjusted EBITDA | ||||||||
| For the Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net loss from continuing operations | $ | (2,149,920 | ) | $ | (3,395,598 | ) | ||
| Interest expense | 154,768 | 322,765 | ||||||
| Interest income | 74,735 | - | ||||||
| Tax expense | 29,530 | - | ||||||
| Depreciation and amortization | 177,564 | 136,741 | ||||||
| Stock-based compensation | 188,622 | 493,348 | ||||||
| Non cash compensation for services | - | 45,000 | ||||||
| Gain on remeasurement | - | - | ||||||
| Gain on change in fair value of warrant liability | 562,997 | 33,566 | ||||||
| Loss from debt extinguishment | - | 1,416,610 | ||||||
| Adjusted EBITDA | $ | (961,704 | ) | $ | (947,568 | ) | ||

© 2026 GlobeNewswire, Inc. All Rights Reserved.











